posteditor

posteditor

/C O R R E C T I O N — Boehringer Ingelheim/

B In the news release, Beamion LUNG-1 study results for zongertinib in treatment-naïve patients with HER2-mutant advanced NSCLC published in The New England Journal of… Login to continue reading Login Sign up for complimentary access Sign Up Now Close